

## Ipsen Announces Third Resupply of Increlex<sup>®</sup> (mecasermin [rDNA origin] Injection) in the U.S. in 2015

- *In collaboration with the FDA, Ipsen will release a third batch of Increlex<sup>®</sup>*
- *Ipsen continues to work with the FDA to release future batches of Increlex<sup>®</sup>*

**Paris (France), 2 March 2015** – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that additional supply of Increlex<sup>®</sup> has been made available in the United States. In collaboration with the FDA (Food and Drug Administration), Ipsen is releasing a third batch of Increlex<sup>®</sup> since product supply was resumed in May 2014.

*“We are pleased that additional Increlex<sup>®</sup> is now available for distribution to treat children in the United States who have severe primary IGF-1 deficiency (IGFD),”* said **Marc De Garidel, Chairman and Chief Executive Officer of Ipsen.** *“We are committed to working closely with regulators with the goal of ensuring that additional lots of Increlex<sup>®</sup> are made available on a timely basis.”*

Information regarding Increlex<sup>®</sup> patient support programs in the US can be found at IPSEN CARES™ at <http://ipsencares.com>.

### **About Increlex<sup>®</sup>**<sup>1</sup>

The active substance in Increlex<sup>®</sup> is a recombinant insulin-like growth factor of human origin (IGF-1). IGF-1 is the direct hormonal mediator of stature and bone growth and must be present for normal growth of bones and cartilage in children. In severe primary IGF-1 deficiency, children’s serum IGF-1 levels are low despite the presence of normal or elevated GH levels. Increlex<sup>®</sup> is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (IGFD), or with growth hormone (GH) gene deletion, who have developed neutralizing antibodies to GH. Severe primary IGFD is defined in the US label by height standard deviation score  $\leq -3.0$  and basal IGF-1 standard deviation score  $\leq -3.0$  and normal or elevated growth hormone (GH).

---

<sup>1</sup> The information on Increlex<sup>®</sup> contained in this press release, including approved indications, relates to the US market.



Increlex<sup>®</sup> is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating Increlex treatment. Increlex is not a substitute to GH for approved GH indications. Increlex has not been studied in children < 2 years of age.

The Increlex<sup>®</sup> supply interruption occurred in mid-June 2013 in the US and in Q3 2013 in Europe and the rest of the world. Resupply in EU and other markets have been effective since December 2013. In the US, the first batch of Increlex<sup>®</sup> was made available for distribution in June of 2014.

### **Important safety Information about Increlex<sup>®</sup> for Patients and Caregivers**

#### **Who should not use Increlex<sup>®</sup>?**

Your child should not take Increlex<sup>®</sup> if your child: has finished growing (the growth plates at the end of the bones are closed), has cancer, OR is allergic to mecasermin or any of the inactive ingredients in Increlex<sup>®</sup>. Increlex<sup>®</sup> has not been studied in children under 2 years of age and should never be used in newborns. Your child should never receive Increlex<sup>®</sup> through a vein.

Before your child takes Increlex<sup>®</sup>, you should tell your child's doctor about:

All of your child's health conditions, including: diabetes, kidney problems, liver problems, allergies, scoliosis (curved spine), pregnancy, or breast-feeding.

All the medicines (prescription and nonprescription), vitamins, and herbal supplements your child takes, especially insulin or other anti-diabetes medicines; some medicines may require dose adjustments.

#### **What are possible side effects of (some of which can be serious)?**

Low blood sugar (hypoglycemia).

Only give your child Increlex<sup>®</sup> right before or right after (20 minutes on either side of) a snack or meal to reduce the chances of hypoglycemia. Signs include dizziness, tiredness, restlessness, hunger, irritability, trouble concentrating, sweating, nausea, and fast or irregular heartbeat. Do not give your child Increlex<sup>®</sup> if your child is sick or cannot eat. Severe hypoglycemia may cause unconsciousness, seizures, or death. People taking Increlex<sup>®</sup> should avoid participating in high risk activities (such as driving) within 2 to 3 hours after an Increlex<sup>®</sup> injection.

Allergic reactions

Your child may have a mild or serious allergic reaction with Increlex<sup>®</sup>. Call your child's doctor right away if your child gets a rash or hives. If hives do occur, they generally appear minutes to hours after the injection as an itchy, raised skin reaction, pale in the middle with a red rim around them, and may sometimes occur at numerous places on the skin. Get medical help immediately if your child has trouble breathing or goes into shock, with symptoms like dizziness, pale, clammy skin, and/or passing out.

Increased pressure in the brain (intracranial hypertension).



Increlex<sup>®</sup>, like growth hormone, can sometimes cause a temporary increase in pressure within the brain. Symptoms include persistent headache, blurred vision, and nausea with vomiting.

Enlarged tonsils and adenoids. Signs include: snoring, difficulty breathing or swallowing, sleep apnea (a condition where breathing stops briefly during sleep), or fluid in the middle ear.

Osteonecrosis/avascular necrosis (occasionally associated with slipped capital femoral epiphysis).

Injection site reactions including: swelling, itchiness, hives, hematoma, bleeding, induration (hardening) increase of fat, pain, redness, or bruising. This can be avoided by changing/rotating the injection site at each injection.

Your child's doctor is your primary source of information about treatment. For more information, please talk to your doctor.

Patient information for Increlex<sup>®</sup> available at <http://increlex.com/pdf/hcp-full-prescribing-information.pdf>

You are encouraged to report negative effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

### **Important safety Information about Increlex<sup>®</sup> for Healthcare Professionals**

#### Contraindications

- Presence of active or suspected malignancy
- Hypersensitivity to mecasermin (rhIGF-1) or any of the inactive ingredients in Increlex<sup>®</sup>
- Intravenous administration
- Closed epiphyses

#### Warnings and precautions

- Hypoglycemic effects: Increlex<sup>®</sup> should be administered 20 minutes before or after a meal or snack, and should not be administered when the meal or snack is omitted.
- Hypersensitivity: Allergic reactions have been reported, including anaphylaxis requiring hospitalization.
- Intracranial hypertension: Funduscopic examination is recommended at the initiation of and periodically during the course of therapy.
- Tonsillar/adenoidal hypertrophy: Patients should have periodic examinations to rule out potential complications.
- Slipped capital femoral epiphysis: Evaluate any child with onset of limp or hip/knee pain.
- Progression of scoliosis: Monitor any child with scoliosis.

Common adverse reactions include: hypoglycemia, local and systemic hypersensitivity, and tonsillar hypertrophy.

Please see the full Prescribing Information for Increlex<sup>®</sup> available at <http://increlex.com/pdf/hcp-full-prescribing-information.pdf>



### **About Ipsen**

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2014. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Moreover, Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information, visit [www.ipсен.com](http://www.ipсен.com).

### **Forward Looking Statement**

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause



damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group's partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

**For further information:**

**Ipsen**

**Media**

Didier Véron  
Senior Vice-Président, Public Affairs  
and Communication  
Tel.: +33 (0)1 58 33 51 16  
Fax: +33 (0)1 58 33 50 58  
E-mail: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

Brigitte Le Guennec  
Corporate External Communication Manager  
Tel.: +33 (0)1 58 33 51 17  
Fax: +33 (0)1 58 33 50 58  
E-mail : [brigitte.le.guennec@ipsen.com](mailto:brigitte.le.guennec@ipsen.com)

**Financial Community**

Stéphane Durant des Aulnois  
Investor Relations Director  
Tel.: +33 (0)1 58 33 60 09  
Fax: +33 (0)1 58 33 50 63  
E-mail: [stephane.durant.des.aulnois@ipsen.com](mailto:stephane.durant.des.aulnois@ipsen.com)

Thomas Peny-Coblentz, CFA  
Investor Relations Deputy Director  
Tel.: +33 (0)1 58 33 56 36  
Fax: +33 (0)1 58 33 50 63  
E-mail: [thomas.peny-coblentz@ipsen.com](mailto:thomas.peny-coblentz@ipsen.com)